Physician
Oncology
Dr. Gary R. Hudes, MD
|
|
Give Review
Gary R. Hudes works in the field of Oncology. He went to State University of New York Downstate Medical Center College of Medicine. He received 1 awards: "Super Doctor". Dr. Gary R. Hudes is a published doctor and has 35 publications published. The lastest was: 'Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line suni...'
Publications
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line suni...
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection.
- A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell Carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor the...
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell Carcinoma.
- Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus.
- Serum amino Acid levels as a biomarker for renal cell Carcinoma.
- Kidney Cancer.
- Selecting targeted therapies for patients with renal cell Carcinoma.
- NCCN Task Force report: optimizing treatment of advanced renal cell Carcinoma with molecular targeted therapy.
- A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate Cancer.
- Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell Carcinoma.
- Global reactivation of epigenetically silenced genes in prostate Cancer.
- Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell Carcinoma.
- Clinical trial experience with temsirolimus in patients with advanced renal cell Carcinoma.
- NCCN clinical practice guidelines in oncology: testicular Cancer.
- NCCN clinical practice guidelines in oncology: kidney Cancer.
- Targeting mTOR in renal cell Carcinoma.
- Role of androgen deprivation therapy for node-positive prostate Cancer.
- NCCN Task Force Report: mTOR inhibition in solid Tumors.
- Sunitinib efficacy against advanced renal cell Carcinoma.
- mTOR as a target for therapy of renal Cancer.
- Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell Carcinoma.
- Impact of zoledronic acid on renal function in patients with Cancer: Clinical significance and development of a predictive model.
- Sunitinib in patients with metastatic renal cell Carcinoma.
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic ...
- Cranial nerve deficits in patients with metastatic prostate Carcinoma: clinical features and treatment outcomes.
- Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.
- Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced Carcinoma of the urothelium.
- Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory Renal cell c...
- Vinblastine and estramustine phosphate in metastatic renal cell Carcinoma: a phase II trial of the Fox Chase Network.
- Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenoCarcinoma.
- Weekly bryostatin-1 in metastatic renal cell Carcinoma: a phase II study.
- Signaling inhibitors in the treatment of prostate Cancer.
- A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell Carcinoma and soft tissue sarcoma.
Schools
SUNY Downstate Medical Center College Of Medicine
Graduate Hospital
Temple University Hospital
University Pa Health Sys Presby M C
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Pennsylvania -
Temple University Hospital -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Fox Chase Cancer Center-American Oncologic Hospital -
Temple University Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Sean B. Odonnell, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Z. Lin, MD |
|
|
Dr. John M. Kaczmar, MD |
|
Dr. Rebecca J. Jaslow, MD |
|
|
Dr. Akhil Chopra, MD |
|
|
Dr. Gataree Ngarmchamnanrith, MD |
|
|
Dr. Matthew T. Hurford, MD |
|
|
Dr. Jennifer M. Matro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shannon R. McCurdy, MD |
|
|
Dr. Lee P. Schacter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Kosteva, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Avnish Bhatia, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rudolph E. Willis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan W. Alley, MD
This Doctor is OpenDoctor Recommended.
|